PMC8044442_01
Response evaluation during the clinical course including changes in imaging and quantitative data. iuPD (immunity unconfirmed progressive disease); icPD (immunity confirmed progressive disease). (A) Trends in the levels of tumor monitoring indicators, including AFP (left Y-axis) and tumor diameters (right Y-axis) corresponding to the treatment timeline. X-axis showing the date of the disease course. The frequency of imaging evaluations is less than that of AFP. (B) Representative images of the CT scan revealed the increasing and decreasing process of both primary and metastatic lesions in the liver and lung after PD-1 antibody (tislelizumab) and sorafenib treatment. Red arrows indicate tumor lesions.
fimmu-12-634559-g001.jpg
PMC8044442_01_fimmu-12-634559-g001.jpg
f1
Pathology indicated hepatocellular carcinoma ( Figure S1 ), while the two lymph nodes were negative. Before the third immunotherapeutic cycle, CT scans indicated that pulmonary lesions almost disappeared while the liver lesions remained stable ( Figure 1B ). During the treatment, AFP reached the highest level (696.18 ng/ml) before the eighth treatment ( Figure 1A ).
The whole clinical timeline of the patient, with major treatment and disease status. DFS, disease-free survival; PFS, progression-free survival.
fimmu-12-634559-g002.jpg
PMC8044442_01_fimmu-12-634559-g002.jpg
f2
Disease progression is shown in  Figure 2 , and except for the maculo-papule, all adverse events are described in  Table 1 . Hematological assessments are shown in the Supplementary material ( Figure S2 ).
Histopathology and immunohistochemistry (IHC) of the lymph node of this patient. Microscopic observation (10x) of H&E staining showed a dense diffuse lymphoid cells infiltration (A). Immunohistochemical staining of CD20 and Bcl-2 expression (20x) showed that tumor cells were positive for CD20 and Bcl-2, respectively (B, D). The Ki-67 proliferative index (20x) was low (C).
fimmu-12-634559-g003.jpg
PMC8044442_01_fimmu-12-634559-g003.jpg
f3
Histological examinations of axillary and inguinal lymph nodes revealed indolent B-cell lymphoma ( Figure 3 ).